company background image
KNSA

Kiniksa Pharmaceuticals NasdaqGS:KNSA Stock Report

Last Price

US$13.44

Market Cap

US$892.0m

7D

21.5%

1Y

23.2%

Updated

03 Oct, 2022

Data

Company Financials +
KNSA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

KNSA Stock Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.

Kiniksa Pharmaceuticals, Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kiniksa Pharmaceuticals
Historical stock prices
Current Share PriceUS$13.44
52 Week HighUS$15.25
52 Week LowUS$7.36
Beta-0.19
1 Month Change17.48%
3 Month Change21.41%
1 Year Change23.19%
3 Year Change90.10%
5 Year Changen/a
Change since IPO-30.97%

Recent News & Updates

Aug 04
Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Kiniksa Pharmaceuticals, Ltd. ( NASDAQ:KNSA ) shareholders will have a reason to smile today, with the analysts making...

Aug 03

Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance

Kiniksa Pharmaceuticals press release (NASDAQ:KNSA): Q2 GAAP EPS of -$0.29 beats by $0.15. Revenue of $26.97M (+250.3% Y/Y) misses by $1.58M. As of June 30, 2022, the company had $138.2 million of cash, cash equivalents, and short-term investments, and no debt. Kiniksa continues to expect ARCALYST net revenue for the full-year 2022 to be between $115 million and $130 million vs consensus of $133.8M. Shares +10% PM.

Shareholder Returns

KNSAUS BiotechsUS Market
7D21.5%0.4%-2.5%
1Y23.2%-25.6%-23.2%

Return vs Industry: KNSA exceeded the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: KNSA exceeded the US Market which returned -23.2% over the past year.

Price Volatility

Is KNSA's price volatile compared to industry and market?
KNSA volatility
KNSA Average Weekly Movement8.9%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: KNSA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: KNSA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015215Sanj Patelhttps://www.kiniksa.com

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd. Fundamentals Summary

How do Kiniksa Pharmaceuticals's earnings and revenue compare to its market cap?
KNSA fundamental statistics
Market CapUS$892.01m
Earnings (TTM)-US$112.07m
Revenue (TTM)US$90.00m

10.4x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KNSA income statement (TTM)
RevenueUS$90.00m
Cost of RevenueUS$28.64m
Gross ProfitUS$61.36m
Other ExpensesUS$173.43m
Earnings-US$112.07m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.61
Gross Margin68.17%
Net Profit Margin-124.52%
Debt/Equity Ratio0%

How did KNSA perform over the long term?

See historical performance and comparison